Literature DB >> 12883530

Stable rAAV-mediated transduction of rod and cone photoreceptors in the canine retina.

J W B Bainbridge1, A Mistry, F C Schlichtenbrede, A Smith, C Broderick, M De Alwis, A Georgiadis, P M Taylor, M Squires, C Sethi, D Charteris, A J Thrasher, D Sargan, R R Ali.   

Abstract

Recombinant adeno-associated virus (rAAV) vectors are attractive candidates for the treatment of inherited and acquired retinal disease. Although rAAV vectors are well characterized in rodent models, a prerequisite to their clinical application in human patients is the thorough evaluation of their efficacy and safety in intermediate animal models. In this study, we describe rAAV-2-mediated expression of GFP reporter gene in retinal cells following local vector delivery in dogs. Subretinal delivery of rAAV.CMV.GFP was performed unilaterally in eight normal dogs from 6 weeks of age. The area of retinal transduction was maximized by the optimization of surgical techniques for subretinal vector delivery by pars-plana vitrectomy and the use of fine-gauge subretinal cannulae to create multiple retinotomies. rAAV-2 vectors mediated efficient stable reporter gene expression in photoreceptors and retinal pigment epithelial cells. We found efficient transduction of cone photoreceptors in addition to rods in both the canine retina and after subretinal vector delivery in another intermediate animal model, the feline retina. GFP expression in dogs was confined to the area of the retinal bleb and was sustained in cells at this site for at least 18 months. Electroretinography demonstrated a modest reduction in global rod-mediated retinal function following subretinal delivery of rAAV.CMV.GFP. Three of the eight animals developed delayed-onset intraocular inflammation, in two cases associated with a serum antibody response to GFP protein. We conclude that rAAV-2 vectors mediate efficient sustained transgene expression in rod and cone photoreceptors following subretinal delivery in this intermediate animal model. The possibility of adverse effects including intraocular immune responses and reduced retinal function requires further investigation prior to clinical applications in patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12883530     DOI: 10.1038/sj.gt.3301990

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  18 in total

1.  Subretinal delivery and electroporation in pigmented and nonpigmented adult mouse eyes.

Authors:  John M Nickerson; Penny Goodman; Micah A Chrenek; Christiana J Bernal; Lennart Berglin; T Michael Redmond; Jeffrey H Boatright
Journal:  Methods Mol Biol       Date:  2012

2.  Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey.

Authors:  Luk H Vandenberghe; Peter Bell; Albert M Maguire; Cassia N Cearley; Ru Xiao; Roberto Calcedo; Lili Wang; Michael J Castle; Alexandra C Maguire; Rebecca Grant; John H Wolfe; James M Wilson; Jean Bennett
Journal:  Sci Transl Med       Date:  2011-06-22       Impact factor: 17.956

3.  Gene therapy prevents photoreceptor death and preserves retinal function in a Bardet-Biedl syndrome mouse model.

Authors:  David L Simons; Sanford L Boye; William W Hauswirth; Samuel M Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-28       Impact factor: 11.205

4.  Genome-wide association study in RPGRIP1(-/-) dogs identifies a modifier locus that determines the onset of retinal degeneration.

Authors:  Keiko Miyadera; Kumiko Kato; Mike Boursnell; Cathryn S Mellersh; David R Sargan
Journal:  Mamm Genome       Date:  2011-12-23       Impact factor: 2.957

Review 5.  Retinal dystrophies and gene therapy.

Authors:  Venki Sundaram; Anthony T Moore; Robin R Ali; James W Bainbridge
Journal:  Eur J Pediatr       Date:  2011-11-15       Impact factor: 3.183

6.  rAAV2/5 gene-targeting to rods:dose-dependent efficiency and complications associated with different promoters.

Authors:  W A Beltran; S L Boye; S E Boye; V A Chiodo; A S Lewin; W W Hauswirth; G D Aguirre
Journal:  Gene Ther       Date:  2010-04-29       Impact factor: 5.250

7.  Differential targeting of feline photoreceptors by recombinant adeno-associated viral vectors: implications for preclinical gene therapy trials.

Authors:  A L Minella; F M Mowat; K L Willett; D Sledge; J T Bartoe; J Bennett; S M Petersen-Jones
Journal:  Gene Ther       Date:  2014-07-24       Impact factor: 5.250

Review 8.  The use of canine models of inherited retinal degeneration to test novel therapeutic approaches.

Authors:  William A Beltran
Journal:  Vet Ophthalmol       Date:  2009 May-Jun       Impact factor: 1.644

9.  Longitudinal evaluation of expression of virally delivered transgenes in gerbil cone photoreceptors.

Authors:  Matthew C Mauck; Katherine Mancuso; James A Kuchenbecker; Thomas B Connor; William W Hauswirth; Jay Neitz; Maureen Neitz
Journal:  Vis Neurosci       Date:  2008 May-Jun       Impact factor: 3.241

10.  AAV retinal transduction in a large animal model species: comparison of a self-complementary AAV2/5 with a single-stranded AAV2/5 vector.

Authors:  S M Petersen-Jones; J T Bartoe; A J Fischer; M Scott; S L Boye; V Chiodo; W W Hauswirth
Journal:  Mol Vis       Date:  2009-09-11       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.